Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients
暂无分享,去创建一个
Madeleine M A Tilanus-Linthorst | Sabine Siesling | S. Siesling | M. Tilanus-Linthorst | R. Bretveld | Sepideh Saadatmand | Reini Bretveld | S. Saadatmand
[1] P. Gøtzsche,et al. Regular self-examination or clinical examination for early detection of breast cancer. , 2003, The Cochrane database of systematic reviews.
[2] K. Rostgaard,et al. Why did the breast cancer lymph node status distribution improve in Denmark in the pre-mammography screening period of 1978–1994? , 2010, Acta oncologica.
[3] A. Jemal,et al. Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.
[4] Madeleine M A Tilanus-Linthorst,et al. Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients , 2015, BMJ.
[5] Donald E. Henson,et al. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .
[6] M. Piccart,et al. Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. , 2014, Journal of the National Cancer Institute.
[7] A. Verbeek,et al. Evaluation of The Netherlands breast cancer screening programme. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] C. Carter,et al. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989, Cancer.
[9] R. Rosenfeld,et al. Cases , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[10] Sally Hunsberger,et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Coebergh,et al. Major Changes in Chemotherapy Regimens Administered to Breast Cancer Patients During 2000–2008 in the Netherlands , 2013, The breast journal.
[12] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.
[13] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[14] J. Wesseling,et al. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands , 2011, Breast Cancer Research and Treatment.
[15] M. K. Tuut,et al. Richtlijn behandeling van het mammacarcinoom , 2008 .
[16] P. V. van Diest,et al. Implementation of sentinel node biopsy in breast cancer patients in the Netherlands. , 2008, European journal of cancer.
[17] K. Czene,et al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. , 2011, Journal of Clinical Oncology.
[18] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[19] K. Gelmon,et al. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] T J Cole,et al. Setting number of decimal places for reporting risk ratios: rule of four , 2015, BMJ : British Medical Journal.
[21] Helena Carreira,et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2) , 2015, The Lancet.
[22] R. Giard,et al. [Summary of the guideline 'Sentinel Node Biopsy for Breast Cancer']. , 2001, Nederlands tijdschrift voor geneeskunde.
[23] Ian O Ellis,et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Klijn,et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. , 2007, European journal of cancer.
[25] A. Jemal,et al. Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[26] A. Giuliano,et al. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] L. Tabár,et al. Real and artificial controversies in breast cancer screening , 2013 .
[28] Jong-Hyeon Jeong,et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] S. Jaffer,et al. Occult Axillary Node Metastases in Breast Cancer are Prognostically Significant: Results in 368 Node Negative Patients With 20-year Follow-up , 2008, Advances in anatomic pathology.
[30] T. Ruers,et al. [Summary of the guideline 'Sentinel node biopsy in breast cancer.' Dutch Work Group 'Sentinel Node Biopsy for Breast Cancer']. , 2000, Nederlands tijdschrift voor geneeskunde.
[31] M. Tuut,et al. [Dutch Institute for Healthcare Improvement guideline, "Treatment of breast cancer"]. , 2002, Nederlands tijdschrift voor geneeskunde.
[32] Paul W Dickman,et al. Regression models for relative survival , 2004, Statistics in medicine.
[33] Gerrit Draisma,et al. The effects of population‐based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy , 2015, International journal of cancer.
[34] P. Bult,et al. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. , 2010, Journal of the National Cancer Institute.